Deep Track Capital VERA Position
Active9-Fund ConvergenceDeep Track Capital initiated a new position in Vera Therapeutics Inc. (VERA) in Q4 2025, holding $142.9M worth of shares across 2,821,135 shares.
VERA is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Atacicept in 167 days (Sep 30, 2026), making the timing of Deep Track's position particularly relevant.
Short interest stands at 13.1% of float with 7.0 days to cover, indicating significant bearish positioning against Deep Track's long thesis.
About Vera Therapeutics Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Full company profile →Short Interest
13.1%
7.0 days to cover
Frequently Asked Questions
Does Deep Track Capital own VERA?
Yes. As of Q4 2025, Deep Track Capital holds 2,821,135 shares of Vera Therapeutics Inc. (VERA) valued at $142.9M. This data comes from their SEC 13F filing.
How many hedge funds own VERA?
9 specialist biotech hedge funds currently hold VERA, including Avoro Capital Advisors, Deerfield Management, Commodore Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy VERA?
Deep Track Capital's position in VERA was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's VERA position increasing or decreasing?
Deep Track Capital initiated a new position in VERA in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VERACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →